Articles with public access mandates - Mark MapstoneLearn more
OverallNIHCIHRDoDNIHRAXA Research Fund, FranceMRCINSERMANRKnut and Alice Wallenberg FoundationSwedish Research CouncilEuropean CommissionFWOFRQSGovernment of SpainBMBFParkinson's UKMichael J Fox FoundationParkinson's Foundation, USACZIHewlettARCNHMRCNSERCMarianne and Marcus Wallenberg FoundationWellcome
Not available anywhere: 7
Memory complaints and memory performance in the menopausal transition
M Weber, M Mapstone
Menopause 16 (4), 694-700, 2009
Mandates: US National Institutes of Health
Impact of mild cognitive impairment on health-related quality of life in Parkinson's disease
W Reginold, S Duff-Canning, C Meaney, MJ Armstrong, S Fox, ...
Dementia and geriatric cognitive disorders 36 (1-2), 67-75, 2013
Mandates: US National Institutes of Health, Canadian Institutes of Health Research
Plasma metabolites related to cellular energy metabolism are altered in adults with Down syndrome and Alzheimer's disease
TJ Gross, E Doran, AK Cheema, E Head, IT Lott, M Mapstone
Developmental Neurobiology 79 (7), 622-638, 2019
Mandates: US National Institutes of Health
Integrative metabolomics science in Alzheimer’s disease: relevance and future perspectives
S Lista, R González-Domínguez, S López-Ortiz, Á González-Domínguez, ...
Ageing Research Reviews 89, 101987, 2023
Mandates: US National Institutes of Health, Government of Spain
Apolipoprotein E genotype impact on memory and attention in older persons: the moderating role of personality phenotype
BP Chapman, RHB Benedict, F Lin, S Roy, A Porteinsson, K Szigeti, ...
International Journal of Geriatric Psychiatry 33 (2), 332-339, 2018
Mandates: US National Institutes of Health
The meaning of a “hippo” response on the Montreal Cognitive Assessment in Parkinson's disease
MJ Armstrong, S Duff-Canning, DF Tang-Wai, S Fox, C Zadikoff, ...
Parkinsonism & Related Disorders 19 (4), 463-465, 2013
Mandates: US National Institutes of Health, Canadian Institutes of Health Research
Proteomic and metabolomic biomarkers of Alzheimer's disease: Opportunities to advance precision medicine and clinical trials
M Petersen, T Gross, SE O’Bryant, M Mapstone
The Neurobiology of Aging and Alzheimer Disease in Down Syndrome, 129-147, 2022
Mandates: US National Institutes of Health
Available somewhere: 101
Plasma phospholipids identify antecedent memory impairment in older adults
M Mapstone, AK Cheema, MS Fiandaca, X Zhong, TR Mhyre, ...
Nature medicine 20 (4), 415-418, 2014
Mandates: US National Institutes of Health
Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes: a case‐control study
MS Fiandaca, D Kapogiannis, M Mapstone, A Boxer, E Eitan, JB Schwartz, ...
Alzheimer's & Dementia 11 (6), 600-607. e1, 2015
Mandates: US National Institutes of Health
Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study
MA Nalls, CY McLean, J Rick, S Eberly, SJ Hutten, K Gwinn, M Sutherland, ...
The Lancet Neurology 14 (10), 1002-1009, 2015
Mandates: US National Institutes of Health, UK Medical Research Council, Parkinson's …
The effect of modafinil on cognitive function in breast cancer survivors
S Kohli, SG Fisher, Y Tra, MJ Adams, ME Mapstone, KA Wesnes, ...
Cancer 115 (12), 2605-2616, 2009
Mandates: US National Institutes of Health
Measuring mild cognitive impairment in patients with Parkinson's disease
C Marras, MJ Armstrong, CA Meaney, S Fox, B Rothberg, W Reginold, ...
Movement Disorders 28 (5), 626-633, 2013
Mandates: US National Institutes of Health, Canadian Institutes of Health Research
The critical need for defining preclinical biomarkers in Alzheimer's disease
MS Fiandaca, ME Mapstone, AK Cheema, HJ Federoff
Alzheimer's & Dementia 10, S196-S212, 2014
Mandates: US National Institutes of Health
Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease
A Vergallo, L Mégret, S Lista, E Cavedo, H Zetterberg, K Blennow, ...
Alzheimer's & Dementia 15 (6), 764-775, 2019
Mandates: Research Foundation (Flanders), National Institute of Health and Medical …
Reconciling subjective memory complaints with objective memory performance in the menopausal transition
MT Weber, M Mapstone, J Staskiewicz, PM Maki
Menopause 19 (7), 735-741, 2012
Mandates: US National Institutes of Health
Predicting conversion from mild cognitive impairment to Alzheimer's disease using neuropsychological tests and multivariate methods
RM Chapman, M Mapstone, JW McCrary, MN Gardner, A Porsteinsson, ...
Journal of clinical and experimental neuropsychology 33 (2), 187-199, 2011
Mandates: US National Institutes of Health
Omics sciences for systems biology in Alzheimer’s disease: State-of-the-art of the evidence
H Hampel, R Nisticò, NT Seyfried, AI Levey, E Modeste, P Lemercier, ...
Ageing Research Reviews 69, 101346, 2021
Mandates: AXA Research Fund, France
Plasma 24-metabolite panel predicts preclinical transition to clinical stages of Alzheimer’s disease
MS Fiandaca, X Zhong, AK Cheema, MH Orquiza, S Chidambaram, ...
Frontiers in neurology 6, 237, 2015
Mandates: US National Institutes of Health
Cognitive and neural effects of vision‐based speed‐of‐processing training in older adults with amnestic mild cognitive impairment: A pilot study
F Lin, KL Heffner, P Ren, ME Tivarus, J Brasch, DG Chen, M Mapstone, ...
Journal of the American Geriatrics Society 64 (6), 1293-1298, 2016
Mandates: US National Institutes of Health
Precision pharmacology for Alzheimer’s disease
H Hampel, A Vergallo, LF Aguilar, N Benda, K Broich, AC Cuello, ...
Pharmacological research 130, 331-365, 2018
Mandates: US National Institutes of Health, AXA Research Fund, France
Publication and funding information is determined automatically by a computer program